TB-500 and BPC-157 show up together constantly in recovery and research discussions. That leads many people to assume they are interchangeable or automatically sold as a set. They are not the same peptide, and telos rx treats their availability very differently.
TB-500 and BPC-157 are two different peptides studied for related biological processes. telos rx does not compound standalone TB-500, but does offer a reviewed BPC-157 plus TB-500 combination protocol.
Start the BPC-157 + TB-500 combo intake →Two different peptides, one common conversation
BPC-157 and TB-500 are frequently discussed side by side. Both are studied for a potential role in tissue repair and recovery processes. That shared context is why they so often appear together in articles, forum threads, and product listings. They come from entirely different biological origins.
BPC-157 is a synthetic peptide based on a protective compound found in human gastric juice. TB-500 is a synthetic fragment of thymosin beta-4, a structural protein found throughout the body. They are studied through different proposed mechanisms, even when the research questions around them sound similar.
Why they are often paired in research and in products
Researchers sometimes examine BPC-157 and TB-500 together. Both are proposed to act on overlapping but distinct pathways involved in cellular repair. Combining two peptides with different proposed mechanisms is a common approach in early-stage peptide research, on the theory that complementary actions might support each other.
That research interest is part of why some clinics, including telos rx, offer combination protocols rather than only single-peptide products. A combination formulation is reviewed as its own distinct product, separate from either peptide sold alone.
Why telos rx offers one but not the other alone
telos rx offers compounded BPC-157 as a standalone product. telos rx does not offer standalone TB-500. The FDA classified TB-500 as a Category 2 bulk substance in late 2023, restricting partner compounding pharmacies from preparing it on its own. That classification does not apply the same way to BPC-157.
What telos rx does offer is the BPC-157 plus TB-500 combination protocol, a distinct, separately reviewed formulation available through the BPC-157 + TB-500 combination page. This is not the same thing as standalone TB-500 being available, and it should not be read that way.
How to think about the difference as a patient
If you are researching these peptides, ask a specific question rather than a general one. Instead of asking whether a clinic carries TB-500, ask whether it offers TB-500 alone, or only as part of a reviewed combination. Those are very different answers with different regulatory footing.
telos rx's standalone BPC-157 page describes that product on its own, separate from the combination protocol. Comparing the two pages side by side is a useful way to understand exactly what telos rx does and does not currently offer.
What the combination protocol involves
The BPC-157 plus TB-500 combination protocol is prescribed and dispensed as its own formulation. It follows the same asynchronous intake and provider review process telos rx uses for its other compounded peptide offerings. It is not simply two separate prescriptions bundled together. It is reviewed as a single product.
Because it is a distinct offering, questions about dosing and administration should go through a licensed provider. They should not be assumed to match either peptide's standalone profile.
Why patients sometimes prefer one path over the other
Some patients researching BPC-157 are not interested in TB-500 at all, and that is a perfectly reasonable position. Standalone BPC-157, described on telos rx's BPC-157 page, may be the simpler and more direct fit if your interest is specifically in that peptide.
Others come to telos rx already familiar with both peptides from research communities and want to understand the combination specifically. Neither path is inherently better. A licensed provider can help you decide which product, if any, fits your history and goals during intake.
It also helps to remember that availability itself is one input into that decision, not the whole decision. A provider conversation should still cover your individual health history regardless of which product you are considering.
How the two peptides are typically described in research
In laboratory research, BPC-157 is usually studied in the context of gastrointestinal and connective tissue processes, given its origin in gastric protective compounds. TB-500 is more often studied in the context of cell migration and structural repair, given its connection to thymosin beta-4 and actin regulation.
These are broad generalizations, and researchers continue to study both peptides across a range of tissue types. The point is not that one peptide has a single narrow use. It is that they arose from different research traditions, even though popular discussion sometimes flattens that distinction.
Understanding this background is useful context, but it should not be mistaken for a clinical claim about what either peptide does in a person. Preclinical research and confirmed clinical effect are two different things, and the gap between them remains wide for both peptides. Treat both descriptions as a starting point for further reading, not a final answer about outcomes.
What to ask before assuming a combination is the better choice
It is tempting to assume that combining two studied peptides must be more effective than either alone. That assumption is not automatically true, and it is not something telos rx claims on the combination protocol's behalf.
What can be said honestly is that the combination is offered as a distinct, reviewed formulation because there was a clear regulatory and clinical basis to formulate it that way. Whether it fits your specific situation is a question for a licensed provider, not a general assumption based on the fact that two peptides sound complementary.
If you are unsure whether you want the combination or standalone BPC-157, say so during intake. A provider can walk through both options rather than assuming you already know which one you want.
A note on sourcing outside a regulated pathway
Both peptides are widely discussed in research and recovery communities. Because of that, they are also sold through unregulated online sellers with no licensed pharmacy or provider involved. Those sources cannot guarantee purity, dosing accuracy, or even that the vial contains what the label claims.
A regulated pathway, where a licensed provider reviews your history and a licensed compounding pharmacy prepares the product, is a meaningfully different experience from ordering a vial from an anonymous website. That difference applies to BPC-157, to the combination protocol, and to any compounded peptide.
Cost or convenience can pull people toward an unregulated source. It is worth weighing that against having no clinical oversight and no verified product quality behind what you receive.
telos rx is LegitScript-certified and works only with partner compounding pharmacies that operate within current regulatory guidance. That structure is part of why the combination protocol, and standalone BPC-157, go through provider review rather than an unmonitored checkout process. It is also why telos rx is transparent about what it does not currently offer, rather than blurring the line to make a sale.
Where to read more, from primary sources
For general background on how the FDA approaches compounding oversight, see the FDA's compounding questions and answers page. For published research involving thymosin beta-4, the natural protein TB-500 is derived from, see this PubMed search of the current literature. Reading primary sources directly is a better habit than relying on secondhand summaries, especially for a peptide whose regulatory status and research base are both still evolving.
Frequently Asked Questions
Are BPC-157 and TB-500 the same peptide?
No. They come from different biological origins and are studied through different proposed mechanisms. They are frequently discussed together because both are studied for tissue repair, but they are distinct compounds with distinct regulatory histories.
Can I get TB-500 alone if I get BPC-157 from telos rx?
No. telos rx offers standalone BPC-157, but not standalone TB-500. TB-500 is only available through the separately reviewed BPC-157 plus TB-500 combination protocol.
Why are the two peptides sold together in a combination product?
Some research interest centers on whether their proposed mechanisms complement each other in supporting tissue repair. telos rx's combination protocol is reviewed as its own distinct formulation, separate from either peptide sold on its own.
Does the combination protocol have the same regulatory status as standalone TB-500?
No. The combination is a distinct, separately reviewed offering. Standalone TB-500 is restricted because of its FDA Category 2 bulk substance classification, which does not apply the same way to a reviewed combination formulation.
How do I know if the combination protocol is right for me?
A licensed provider can review your history and goals to determine whether the BPC-157 plus TB-500 combination fits your situation. That conversation happens through the standard telos rx intake process, and nothing is approved automatically.
Where can I compare the standalone and combination options?
telos rx's BPC-157 page describes the standalone product, and the BPC-157 plus TB-500 combination page describes the combination protocol. Reviewing both is the clearest way to see what is currently offered, and both pages are kept current as the program evolves.
telos rx is LegitScript-certified. Compounded medication is not FDA-approved and is prepared under federal compounding regulations by partner compounding pharmacies. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.
Questions about the BPC-157 + TB-500 combination protocol? Message the telos rx care team or read more on the BPC-157 + TB-500 combination page.